SCHEDULE: Ally Bridge Group Boosts Stake in ProMIS Neurosciences

Ally Bridge Group and its affiliates, led by Fan Yu, increased their beneficial ownership in ProMIS Neurosciences Inc. to 17.0% following a recent offering and a reverse stock split.

Summary

• Ally Bridge Group entities and Fan Yu collectively increased their beneficial ownership in ProMIS Neurosciences Inc. to 1,644,397 common shares, representing 17.0% of the class.
• The increase in ownership is primarily due to the closing of a previously disclosed offering on February 3, 2026.
• In this offering, Ally Bridge MedAlpha Master Fund L.P. purchased 164,881 common shares and warrants for approximately $2,000,006.53.
• ABG V-SIV IX Limited purchased 329,760 common shares and warrants for approximately $3,999,988.80.
• ABG V-SIV X Limited purchased 206,100 common shares and warrants for approximately $2,499,993.
• The Issuer entered into a 2026 Registration Rights Agreement on February 3, 2026, obligating it to file a registration statement for the resale of the newly issued common shares and shares underlying the warrants.
• The reported share amounts reflect a 1-for-25 reverse stock split that took effect on November 28, 2025.
• Total common shares outstanding immediately after the offering were 8,967,693.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant capital infusion from a specialized investor group can provide necessary funding and signal confidence, despite the potential for future dilution from warrants and the preceding reverse stock split.

Positives

• Significant capital infusion into ProMIS Neurosciences Inc. from Ally Bridge Group entities, totaling approximately $8.5 million.
• The investment by a prominent life science investor group like Ally Bridge Group could signal confidence in ProMIS Neurosciences' future prospects.

Negatives

• The issuance of new shares and warrants in the offering could lead to potential dilution for existing shareholders upon warrant exercise.
• The need for a reverse stock split often indicates a low share price, which can be perceived negatively by the market.

Future Outlook

ProMIS Neurosciences Inc. is required to prepare and file a registration statement with the SEC covering the resale of the common shares issued in the recent offering, along with the common shares underlying the warrants.

Industry Context

StockSavvy.ai notes that the life sciences and biotechnology sectors frequently rely on capital raises to fund research and development, especially for companies like ProMIS Neurosciences focused on neurodegenerative diseases. The involvement of a specialized investor group like Ally Bridge Group, known for its focus on global life science investments, suggests a strategic interest in the company's pipeline or market position. The reverse stock split, while often a sign of a struggling stock, can also be a strategic move to meet listing requirements or attract institutional investors by increasing per-share price.

Stakeholder Impact

• Shareholders: Potential for dilution from the exercise of warrants, but also benefit from the capital infusion and potential validation from a significant investor. The reverse stock split impacts share count and price per share.
• Company (ProMIS Neurosciences Inc.): Receives significant capital to fund operations, but incurs obligations under the registration rights agreement.

Next Steps

• ProMIS Neurosciences Inc. is required to prepare and file a registration statement with the SEC for the resale of common shares and warrant-underlying shares.

Key Dates

Recommendation

While the capital raise provides essential funding and the backing of a specialized investor group is a positive signal, the preceding reverse stock split and the potential for future dilution from warrants introduce elements of uncertainty. Investors should hold to observe how the company utilizes the new capital and how the market reacts to the registration of shares for resale, which could create selling pressure.

Keywords

ProMIS Neurosciences, Ally Bridge Group, Fan Yu, Schedule 13D, beneficial ownership, common shares, warrants, reverse stock split, registration rights agreement, biotechnology investment, life sciences